Welcome to our dedicated page for Cue Biopharma news (Ticker: CUE), a resource for investors and traders seeking the latest updates and insights on Cue Biopharma stock.
Cue Biopharma, Inc. (Nasdaq: CUE) is a clinical-stage biopharmaceutical company headquartered in Boston, Massachusetts and focused on developing injectable biologics that selectively engage disease-specific T cells. News about Cue Biopharma often centers on its Immuno-STAT platform, clinical data from its CUE-100 series programs, and progress in autoimmune disease and oncology.
Investors and followers of CUE stock can use this page to review company press releases and third-party coverage related to Cue Biopharma’s pipeline. Typical updates include clinical trial readouts for CUE-101 in HPV16+ head and neck cancer and CUE-102 in WT1-expressing tumors, as well as developments around CUE-401, the company’s lead autoimmune asset designed to promote regulatory T cell–mediated tolerance.
News flow also highlights Cue Biopharma’s strategic collaborations and corporate milestones. Examples include agreements with Boehringer Ingelheim for CUE-501, a differentiated B cell depletion therapy for autoimmune and inflammatory diseases, and a collaboration and license agreement with ImmunoScape to advance a Seed-and-Boost cell therapy approach for solid tumors using the CUE-100 series. Financial updates, such as quarterly results, collaboration revenue disclosures and public equity offerings under the company’s shelf registration statement, are also common topics.
By following this CUE news feed, readers can track regulatory interactions, investigator-sponsored trials, leadership transitions, licensing deals and financing activities that may influence Cue Biopharma’s development trajectory. Bookmark this page to quickly access the latest headlines and historical announcements related to Cue Biopharma and its Immuno-STAT-based biologics.
Cue Biopharma (Nasdaq: CUE) is set to present at The Promise of Interleukin-2 Therapy Conference in Paris, France, from September 4-7, 2024. Two key presentations are scheduled:
1. On September 6, Dr. Steven Quayle will present preclinical data on CUE-401, a novel bispecific fusion protein that induces and expands regulatory T cells through co-delivery of IL-2 and TGF-β.
2. On September 7, Dr. Matteo Levisetti will discuss the clinical safety and efficacy of the company's lead oncology programs CUE-101 and CUE-102, which selectively target IL-2 to tumor-specific T cells for enhanced efficacy and safety profiles.
These presentations highlight Cue Biopharma's innovative approach in developing therapeutic biologics to modulate disease-specific T cells.
Cue Biopharma (Nasdaq: CUE) reported Q2 2024 financial results and recent business highlights. Key points include:
1. CUE-101 showed promising results in HPV+ R/M HNSCC, with 46% ORR in 1L therapy and 20.8 months mOS in 2L+ monotherapy.
2. CUE-102 demonstrated dose-dependent T cell activation and anti-tumor activity in refractory metastatic cancers.
3. Q2 2024 collaboration revenue increased to $2.7 million from $1.4 million in Q2 2023.
4. R&D expenses decreased to $9.5 million in Q2 2024 from $10.7 million in Q2 2023.
5. Cash and cash equivalents were $30.0 million as of June 30, 2024, expected to fund operations through Q2 2025.
Cue Biopharma (Nasdaq: CUE) has announced a conference call and webcast scheduled for August 19, 2024, at 4:30 p.m. EDT to provide a business update. The company will discuss its recent restructuring and strategic prioritization, focusing on enhancing near-term shareholder value by:
- Refocusing resources on autoimmune programs CUE-401 and CUE-501
- Allowing data from ongoing oncology trials for CUE-101 and CUE-102 to mature
The call will also cover clinical and business updates, market opportunities, and anticipated near-term milestones. Investors can access the call via phone or webcast, with options for both domestic and international participants.
Cue Biopharma (Nasdaq: CUE) has announced a strategic shift to prioritize its autoimmune programs, aiming to focus on near-term and intermediate value creation. The company will retain its oncology programs as clinical data continues to mature. This restructuring is expected to reduce annualized capital and workforce requirements by approximately 25%.
Key points:
- Focus on autoimmune programs CUE-401 and CUE-501
- Retention of oncology programs CUE-101 and CUE-102
- Projected annual cash burn reduction to approximately $30 million
- Workforce reduction of about 25% across various departments
- Cash runway expected to extend into mid-year 2025
Cue Biopharma has presented updated data from its Phase 1 trial of CUE-101 at the 2024 ASCO Annual Meeting, revealing promising results for HPV+ head and neck cancer. The combination of CUE-101 and pembrolizumab in first-line (1L) treatment showed a 46% overall response rate (ORR) and a 96% 12-month overall survival (OS). For second-line (2L) and beyond, median overall survival (mOS) was 20.8 months with CUE-101 monotherapy, significantly higher than historical comparisons. No significant safety concerns emerged. Additionally, early data from CUE-102 indicated positive immune response and tolerability.
Cue Biopharma, a clinical-stage biopharmaceutical company, will participate in two significant investor healthcare conferences this June 2024. The company, listed on Nasdaq with the ticker CUE, focuses on developing therapeutic biologics targeting disease-specific T cells.
On June 6, Cue Biopharma will present at the Jefferies Global Healthcare Conference in New York, discussing its progress in oncology and autoimmune platforms. The presentation by Anish Suri, Ph.D., President and Chief Scientific Officer, will be available via webcast.
On June 24, the company will participate in the Oppenheimer Novel Targets and Immunology Summit, also in New York. Dr. Suri will join a panel to discuss repurposing cancer targets for immunology. These events will provide updates on clinical and preclinical advancements and strategic approaches.
Cue Biopharma, Inc. reported their first-quarter 2024 financial results, showcasing an increase in collaboration revenue to $1.7 million due to partnerships. They highlighted advancements in clinical trials for CUE-101 and CUE-102, as well as the expansion of their pipeline to include programs for autoimmune and inflammatory diseases. The company emphasized progress in their autoimmune program, CUE-401, with Ono Pharmaceutical, and the development of the bispecific Immuno-STAT CUE-500 series. Financially, Cue Biopharma reported $41.0 million in cash and cash equivalents as of March 31, 2024, with expectations to fund operations into the first quarter of 2025.
Cue Biopharma, Inc. (Nasdaq: CUE) is set to present at the 20th PEGS Boston Summit with two poster presentations discussing their innovative Immuno-STAT biologics for targeting autoimmune diseases and immuno-oncology. The presentations will cover the CUE-500 series for depleting B cells in autoimmune diseases and the Immuno-STAT platform for cancer and inflammatory diseases.
Cue Biopharma, Inc. (Nasdaq: CUE) will participate in a fireside chat at The Citizens JMP Life Sciences Conference in New York to discuss current oncology and autoimmune disease strategies and progress. The webcast of the chat will be available on the company's website.
FAQ
What is the current stock price of Cue Biopharma (CUE)?
What is the market cap of Cue Biopharma (CUE)?
